Talking Euretina

Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.

A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.

Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.

New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.

A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches